The Inhibitory Effects of Interleukin-1 on Growth Hormone Action During Catabolic Illness

Vitamins and Hormones

Volumn 74, Issue , 2006, Pages 317-340

  Cooney, Robert N ^a   Shumate, Margaret ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; INTERLEUKIN 1; SOMATOMEDIN C;

ANIMAL; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; RAT; REVIEW; SEPSIS;

ANIMALS; GENE EXPRESSION REGULATION; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-1; RATS; SEPSIS;

EID: 33947726760     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(06)74013-4     Document Type: Review

References (137)

1. Adams T.E., Hansen J.A., Starr R., Nicola N.A., Hilton D.J., and Billestrup N. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J. Biol. Chem. 273 (1998) 1285-1287
2. Ahluwalia A., Clodfelter K.C., and Waxman D.J. Sexual dimorphism of rat liver gene expression: Regulatory role of growth hormone revealed by deoxyribonucleic acid microarray analysis. Mol. Endocrinol. 18 (2004) 747-760
3. Akira S., and Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4 (2004) 499-511
4. Alexander W.S., Starr R., Metcalf D., Nicholson S.E., Farley A., Elefanty A.G., Brysha M., Kile B.T., Richardson R., Baca M., Zhang J.G., Willson T.A., et al. Suppressors of cytokine signaling (SOCS): Negative regulators of signal transduction. J. Leukoc. Biol. 66 (1999) 588-592
5. An M.R., and Lowe W.L.J. The major promoter of the rat insulin-like growth factor-I gene binds a protein complex that is required for basal expression. Mol. Cell Endocrinol. 114 (1995) 77-89
6. Arend W.P., Welgus H.G., Thompson R.C., and Eisenberg S.P. Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J. Clin. Invest. 85 (1990) 1694-1697
7. Arend W.P. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J. Clin. Invest. 88 (1991) 1445-1451
8. Arend W.P., Smith Jr. M.F., Janson R.W., and Joslin F.G. IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. J. Immunol. 147 (1991) 1530-1536
9. Argetsinger L.S., Campbell G.S., Yang X., Witthuhun B.A., Silvennoinen O., Ihle J.N., and Carter-Su C. Identification of Jak2 as a growth hormone receptor-associated tyrosine kinase. Cell 74 (1993) 237-244
10. Auron P.E., and Webb A.C. Interleukin-1: A gene expression system regulated at multiple levels. Eur. Cytokine Netw. 5 (1994) 573-592
11. Bagby G.C. Interleukin-1 and hematopoiesis. Blood Rev. 3 (1989) 152-161
12. Barton E.R., Morris L., Musaro A., Rosenthal N., and Sweeney H.L. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell Biol. 157 (2002) 137-148
13. Bergad P.L., Shis H.M., Towle H.C., Schwarzenberg S.J., and Berry S.A. Growth hormone induction of hepatic serine protease inhibitor 2.1 transcription is mediated by a Stat5-related factor binding synergistically to two γ-activated sites. J. Biol. Chem. 270 (1995) 24903-24910
14. Bergad P.L., Schwarzenberg S.J., Humbert J.T., Morrison M., Amarasinghe S., Towle H.C., and Berry S.A. Inhibition of growth hormone action in models of inflammation. Am. J. Physiol. Cell Physiol. 279 (2000) C1906-C1917
15. Bichell D.P., Kikuchi K., and Rotwein P. Growth hormone rapidly activates insulin-like growth factor-I gene transcription in vivo. Mol. Endocrinol. 6 (1992) 1899-1908
16. Bistrian B.R., Schwartz J., and Istfan N.W. Cytokines, muscle proteolysis, and the catabolic response to infection and inflammation. Proc. Soc. Exp. Biol. Med. 200 (1992) 220-223
17. Boisclair Y.R., Wang J., Shi J., Hurst K.R., and Ooi G.T. Role of the suppressor of cytokine signaling-3 in mediating the inhibitory effects of interleukin-1β on the growth hormone-dependent transcription of the acid-labile subunit gene in liver cells. J. Biol. Chem. 275 (2000) 3841-3847
18. Cannon J.G., Friedberg J.S., Gelfand J.A., Tompkins R.G., Burke J.F., and Dinarello C.A. Circulating interleukin-1β and tumor necrosis factor-α concentrations after burn injury in humans. Crit. Care Med. 20 (1992) 1414-1419
19. Carter-Su C., and Smit L.S. Signaling via JAK tyrosine kinases: Growth hormone receptor as a model system. Recent Prog. Horm. Res. 53 (1998) 61-83
20. Carter-Su C., Schwartz J., and Smit L.S. Molecular mechanism of growth hormone action. Ann. Rev. Physiol. 58 (1996) 187-207
21. Casey L.C., Balk R.A., and Bone R.C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 119 (1993) 771-778
22. Cerra F.B., Siegal J.H., Coleman B., Border J.R., and McNenamy R.R. Septic autocannibalism: A failure of exogenous nutritional support. Ann. Surg. 192 (1980) 570-580
23. Cerretti D.P., Kozlosky C.J., Mosley B., Nelson N., van Ness K., Greenstreet T.A., March C.J., Kronheim S.R., Druck T., Cannizaro L.A., Huebner K., and Black R.A. Molecular cloning of the interleukin-1 beta converting enzyme. Science 256 (1992) 97-100
24. Chow J.C., Ling P.R., Qu Z., Laviola L., Ciccarone A., Bistrian B.R., and Smith R.J. Growth hormone stimulates tyrosine phosphorylation of JAK2 and STAT5 but not insulin response substrate-1 or SHC proteins in liver and skeletal muscle of normal rats in vivo. Endocrinology 137 (1996) 2880-2886
25. Coculescu M. Blood-brain barrier for human growth hormone and insulin-like growth factor-I. J. Pediatr. Endocrinol. Metab. 12 (1999) 113-124
26. Colotta F., Re F., Muzio M., Bertini R., Polentarutti N., Sironi M., Giri J.G., Dower S.K., Sims J.E., and Mantovani A. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-1. Science 261 (1993) 472-474
27. Cooney R.N. Suppressors of cytokine signaling (SOCS): Inhibitors of the JAK/STAT pathway. Shock 17 (2002) 83-90
28. Cooney R.N., Kimball S.R., and Vary T.C. Regulation of skeletal muscle protein turnover during sepsis: Mechanisms and mediators. Shock 7 (1997) 1-16
29. Cooney R.N., Maish III G.O., Gilpin T., Shumate M.L., Lang C.H., and Vary T.C. Mechanism of IL-1-induced inhibition of protein synthesis in skeletal muscle. Shock 11 (1999) 235-241
30. Cooney R.N., Kimball S.R., Eckman R., Maish G.O., Shumate III M., and Vary T.C. TNF-binding protein ameliorates inhibition of skeletal muscle protein synthesis during sepsis. Am. J. Physiol. Endocrinol. Metab. 276 39 (1999) E611-E619
31. Dahn M.S., Lange P., and Jacobs L.A. Insulin-like growth factor I production is inhibited in human sepsis. Arch. Surg. 123 (1988) 1409-1414
32. Davey H.W., McLachlan M.J., Wilkins R.J., Hilton D.J., and Adams T.E. STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver. Mol. Cell Endocrinol. 158 (1999) 111-116
33. Davey H.W., Xie T., McLachlan M.J., Wilkins R.J., Waxman D.J., and Grattan D.R. STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology 142 (2001) 3836-3841
34. Davidson M.B. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr. Rev. 8 (1987) 115-131
35. Defalque D., Brandt N., Ketelslegers J.M., and Thissen J.P. GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptors. Am. J. Physiol. Endocrinol. Metab. 276 (1999) E565-E572
36. Denson L.A., Menon R.K., Shaufl A., Bajwa H.S., Williams C.R., and Karpen S.J. TNF-α downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding. J. Clin. Invest. 107 (2001) 1451-1458
37. Dinarello C.A. Interleukin-1 and interleukin-1 antagonism. Blood 77 (1991) 1627-1652
38. Dinarello C.A. Biological basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
39. Dinarello C.A. Interleukin-1. Cytok. Growth Factor Rev. 8 4 (1997) 253-265
40. Dinarello C.A. Proinflammatory cytokines. Chest 118 (2000) 503-508
41. Dinarello C.A. Blocking IL-1 in systemic inflammation. JEM 201 (2005) 1355-1359
42. Dinarello C.A., and Wolff S.M. The role of interleukin-1 in disease. N. Engl. J. Med. 328 (1993) 106-113
43. Dinarello C.A., Clowes G.H., Gordon A.H., Sapavis A., and Wolff S.M. Cleavage of human interleukin-1: Isolation of a peptide from the plasma of febrile humans and activated monocytes. J. Immunol. 133 (1984) 1332-1338
44. Dunne A., and O'Neill L.A.J. The interleukin-1 receptor/Toll-like receptor superfamily: Signal transduction during inflammation and host defense. STKE 171 (2003) 1-17
45. Eastgate J.A., Symons J.A., Wood N.C., Grinlinton F.M., di Giovine F.S., and Duff G.W. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 2 (1988) 706-709
46. Fan J., Molina P.E., Gelato M.C., and Lang C.H. Differential tissue regulation of insulin-like growth factor-I content and binding proteins after endotoxin. Endocrinology 134 (1994) 1685-1692
47. Fan J., Char D., Bagby G.J., Gelato M.C., and Lang C.H. Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor. Am. J. Physiol. 269 (1995) R1204-R1212
48. Fan J., Char D., Kolasa A.J., Pan W., Maitra S.R., Patlak C.S., Spolarics Z., Gelato M.C., and Lang C.H. Alterations in hepatic production and peripheral clearance of IGF-I after endotoxin. Am. J. Physiol. Endocrinol. Metab. 269 (1995) E33-E42
49. Fan J., Wojnar M., Theodorakis M., and Lang C.H. Regulation of insulin-like growth factor (IGF-I) mRNA and peptide and IGF-binding proteins by interleukin-1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 270 (1996) R621-R629
50. Fischer E., Marano M.A., Barber A.E., Hudson A., Lee K., Rock C.S., Hawes A.S., Thompson R.C., Hayes T.J., Anderson T.D., Benjamin W.R., Lowry S.R., et al. Comparison between effects of interleukin-1α administration and sublethal endotoxemia in primates. Am. J. Physiol. 261 (1991) R442-R452
51. Flores-Morales A., Greenhalgh C.J., Norstedt G., and Rico-Bautista E. Negative regulation of GH receptor signaling. Mol. Endocrin. 20 (2006) 241-253
52. Fong Y., Moldawer L.L., Marano M., Wei H., Barger A., Manogue K., Tracey K.J., Kuo G., Fischman D.A., Cerami A., and Lowry S.F. Cachetin, TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am. J. Physiol. Regul. Integr. Comp. Physiol. 256 (1989) R659-R665
53. Freshney N.W., Rawlinson L., Guesdon F., Jones E., Cowley S., Hsuan J., and Saklatvala J. Interleukin-1 activates a novel protein cascade that results in the phosphorylation of hsp27. Cell 78 (1994) 1039-1049
54. Frost R.A., and Lang C.H. Regulation of insulin-like growth factor-I in skeletal muscle and muscle cells. Minerva Endocrinol. 28 (2003) 53-73
55. Gebert C.A., Park S.H., and Waxman D.J. Regulation of STAT5b activation by the temporal pattern of growth hormone stimulation. Mol. Endocrinol. 11 (1997) 400-414
56. Gebert C.A., Park S.H., and Waxman D.J. Termination of growth hormone pulse-induced STAT5b signaling. Mol. Endocrinol. 13 (1999) 38-56
57. Granowitz E.V., Mancilla J., Clark B.D., and Dinarello C.A. The IL-1 receptor antagonist inhibits IL-1 binding to the type II IL-1 receptor. J. Biol. Chem. 266 (1991) 14147-14150
58. Greenfeder S.A., Nunes P., Kwee L., Labow M., Chizzonite R.A., and Ju G. Molecular cloning and characterization of a second subunit of the interleukin-1 receptor complex. J. Biol. Chem. 270 (1995) 13757-13765
59. Guirao X., and Lowry S.F. Biologic control of injury and inflammation: Much more than too little or too late. World J. Surg. 20 (1996) 437-446
60. Hansen J.A., Lindberg K., Hilton D.J., Nielsen J.H., and Billestrup N. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol. Endocrinol. 13 (1999) 1832-1843
61. Hauser C., Saurat J.H., Schmitt A., Jaunin F., and Dayer J.M. Interleukin-1 is present in normal human epidermis. J. Immunol. 136 (1986) 3317-3323
62. Hermansson M., Wickelgren R.B., Hammarqvist F., Bjarnason R., Wennstrom I., Wernerman J., Carlsson B., and Carlsson L.M. Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction-based assay: Demonstration of reduced expression after elective surgery. J. Clin. Endocrinol. Metab. 82 (1997) 421-428
63. Herrington J., and Carter-Su C. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol. Metab. 12 (2001) 252-257
64. Hodge C., Liao J., Stofega M., Guan K., Carter-Su C., and Schwartz J. Growth hormone stimulates phosphorylation and activation of Elk-1 and expression of c-fos, egr-1, and junB through activation of extracellular signal-related kinases 1 and 2. J. Biol. Chem. 273 (1998) 31327-31336
65. Hong-Brown L.Q., Brown C.R., Cooney R.N., Frost R.A., and Lang C.H. Sepsis-induced muscle growth hormone resistance occurs independently of STAT5 phosphorylation. Am. J. Physiol. Endocrinol. Metab. 285 (2003) E63-E72
66. Horvath C.M., and Darnell J.E. The state of the STATs: Recent developments in the study of signal transduction to the nucleus. Curr. Opin. Cell. Biol. 9 (1997) 233-239
67. Ihle J.N., Witthuhn B.A., Quelle F.W., Yamamoto K., and Silvennoinen O. Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 13 (1995) 369-398
68. Jeay S., Sonenshein G.E., Postel-Vinay M.C., Kelly P.A., and Baixeras E. Growth hormone can act as a cytokine controlling survival and proliferation of immune cells: New insights into signaling pathways. Mol. Cell. Endocrinol. 188 (2002) 1-7
69. Jenkins R.C., and Ross R.J. Acquired growth hormone resistance in catabolic states. Baillieres Clin. Endocrinol. Metab. 10 (1996) 411-419
70. Jurasinski C.V., and Vary T.C. Insulin-like growth factor-I accelerates protein synthesis in skeletal muscle during sepsis. Am. J. Physiol. 269 (1995) E977-E981
71. Ketelslegers J.M., Maiter D., Maes M., Underwood L.E., and Thissen J.P. Nutritional regulation of the growth hormone and insulin-like growth factor-binding proteins. Horm. Res. 45 (1996) 252-257
72. Kopchick J.J., and Andry J.M. Growth hormone (GH), GH receptor, and signal transduction. Mol. Genet. Metab. 71 (2000) 293-314
73. Lang C.H., Fan J., Cooney R.N., and Vary T.C. IL-1ra attenuates sepsis-induced alterations in the IGF system and protein synthesis. Am. J. Physiol. 270 (1996) E430-E437
74. Lang C.H., Pollard V., Traber L.D., Frost R.A., Gelato M.C., and Prough D.S. Acute alterations in growth hormone-insulin-like growth factor axis in humans injected with endotoxin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 273 (1997) R371-R378
75. Lang C.H., Fan J., Wojnar M.M., Vary T.C., and Cooney R. Role of central IL-1 in regulating peripheral IGF-I during endotoxemia and sepsis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 274 (1998) 956-962
76. Lang C.H., Frost R.A., Ejiofor J., Lacy D.B., and McGuinness O.P. Hepatic production and intestinal uptake of IGF-I: Response to infection. Am. J. Physiol. Gastrointest. Liver Physiol. 275 6 (1998) G1291-G1298
77. Le Cam A., Conception P., and Thissen J.P. Growth hormone-mediated transcriptional activation of the rat serine protease inhibitor 2. 1 gene involves both interleukin-1β-sensitive and -insensitive pathways. Biochem. Biophys. Res. Commun. 253 (1998) 311-314
78. Le Roith D., Bondy C., Yakar S., Liu J.L., and Butler A. The somatomedin hypothesis: 2001. Endocr. Rev. 22 (2001) 53-74
79. Liao W., Rudling M., and Angelin B. Contrasting effects of growth hormone and insulin-like growth factor I on the biological activities of endotoxin in the rat. Endocrinology 138 (1997) 289-295
80. Liu J.P., Baker J., Perkins A.S., Robertson E.J., and Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75 (1993) 59-72
81. Lombardi G., Colao A., Ferone D., Marzullo P., Orio F., Longobardi S., and Merola B. Effect of growth hormone on cardiac function. Horm. Res. 48 (1997) 38-42
82. Lynch G.S., Cuffe S.A., Plant D.R., and Gregorevic P. IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice. Neuromuscul. Disord. 11 (2001) 260-268
83. Mao Y., Ling P.R., Fitzgibbons T.P., McCowen K.C., Frick G.P., Bistrian B.R., and Smith R.J. Endotoxin-induced inhibition of growth hormone receptor signaling in rat liver in vivo. Endocrinology 140 (1999) 5505-5515
84. March C.J., Moseley B., Larsen A., Cerretti D.P., Braedt G., Price V., Gillis S., Henney C.S., Kronheim S.R., Grabstein K., Conlon P.J., Hopp T.P., et al. Cloning, sequence, and expression of two distinct human interleukin-1 complementary DNAs. Nature 315 (1985) 641-647
85. Marshall J.C. SIRS and MODS: What is their relevance to the science and practice of intensive care?. Shock 14 (2000) 586-589
86. Martin M.U., and Wesche H. Summary and comparison of the signaling mechanisms of the toll/interleukin-1 receptor family. Biochim. Biophys. Acta 1592 (2002) 265-280
87. Matthews L.S., Enberg B., and Norstedt G. Regulation of rat growth hormone receptor gene expression. J. Biol. Chem. 264 (1989) 9905-9919
88. Mittanck D.W., Kim S.W., and Rotwein P. Essential promoter elements are located within the 5″ untranslated region of human insulin-like growth factor-I exon I. Mol. Cell Endocrinol. 126 (1997) 153-163
89. Moldawer L.L., Svaninger G., Gelin J., and Lundholm K.G. Interleukin-1 and tumor necrosis factor do not regulate protein balance in skeletal muscle. Am. J. Physiol. 253 (1987) C766-C773
90. Ooi G.T., Kelley R.H., Poy M.N., Rechler M.M., and Boisclair Y.R. Binding of STAT5a and STAT5b to a single element resembling a γ-interferon-activated sequence mediates the growth hormone induction of the mouse acid-labile subunit promoter in liver cells. Mol. Endocrinol. 12 (1998) 675-687
91. Okusawa S., Gelfand J.A., Ikejima T., Connolly R.J., and Dinarello C.A. Interleukin 1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J. Clin. Invest. 81 (1988) 1162-1172
92. Park S.H., Yamashita H., Rui H., and Waxman D.J. Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: Impact on STAT5 transcriptional activity. Mol. Endocrinol. 15 (2001) 2157-2171
93. Peisen J.N., McDonnell K.J., Mulroney S.E., and Lumpkin M.D. Endotoxin-induced suppression of the somatotropic axis is mediated by interleukin-1 beta and corticotropin-releasing factor in the juvenile rat. Endocrinology 136 (1995) 3378-3390
94. Priego T., Ibanez de Caceres I., Martin A.I., Villanua M.A., and Lopez-Calderon A. Glucocorticoids are not necessary for the inhibitory effect of endotoxic shock on serum IGF-I and hepatic IGF-I mRNA. J. Endocrinol. 172 (2002) 449-456
95. Ram P.A., and Waxman D.J. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J. Biol. Chem. 274 (1999) 35553-35561
96. Ram P.A., Park S.H., Choi H.K., and Waxman D.J. Growth hormone activation of Stat 1, Stat 3, and Stat 5 in rat liver. Differential kinetics of hormone desensitization and growth hormone stimulation of both tyrosine phosphorylation and serine/threonine phosphorylation. J. Biol. Chem. 271 (1996) 5929-5940
97. Rennie M.J. Muscle protein turnover and the wasting due to injury and disease. Br. Med. Bull. 41 (1985) 257-264
98. Ribaux P., Gjinovci A., Sadowski H.B., and Iynedjian P.B. Discrimination between signaling pathways in regulation of specific gene expression by insulin and growth hormone in hepatocytes. Endocrinology 143 (2002) 3766-3773
99. Rotwein P. Part I. Molecular Biology of the IGF System. Molecular Biology of IGF-I and IGF-II. In: Rosenfield R., and Roberts C.J. (Eds). "The IGF System, Molecular Biology, Physiology, and Clinical Applications" (1999), Humana, Totowa, NJ 19-35
100. Roubenoff R., Roubenoff R.A., Ward L.M., and Stevens M.B. Catabolic effects of high-dose corticosteroids persist despite therapeutic benefit in rheumatoid arthritis. Am. J. Clin. Nutr. 52 (1990) 1113-1117
101. Roubenoff R., Roubenoff R.A., Cannon J.G., Kehayias J.J., Zhuang H., Dawson-Hughes B., Dinarello C.A., and Rosenber I.H. Rheumatoid cachexia: Cytokine-drive hypermetabolism accompanying reduced body cell mass in chronic inflammation. J. Clin. Invest. 93 (1994) 2379-2386
102. Roux-Lombard P. The interleukin family. Eur. Cytokine Netw. 9 (1998) 565-576
103. Saxne T., Pallodino Jr. M.A., Heinegard D., Talal N., and Wollheim F.A. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31 (1988) 1041-1044
104. Schindler R., Clark B.D., and Dinarello C.A. Dissociation between interleukin-1b mRNA and protein synthesis in human peripheral mononuclear cells. J. Biol. Chem. 265 (1990) 10232-10237
105. Shoba L.N., Newman M., Liu W., and Lowe Jr. W.L. LY294002, an inhibitor of phosphatidylinositol 3-kinase, inhibits GH-mediated expression of the IGF-I gene in rat hepatocytes. Endocrinology 142 (2001) 3980-3986
106. Shumate M.L., Yumet G., Ahmed T.A., and Cooney R.N. Interleukin-1 inhibits the induction of insulin-like growth factor-I by growth hormone in CWSV-1 hepatocytes. Am. J. Physiol. Gastrointes. Liver Physiol. 289 (2005) G227-G239
107. Simar-Blanchet A.E., Legraverend C., Thissen J.P., and Le Cam A. Transcription of the rat serine protease inhibitor 2. 1 gene in vivo: Correlation with GAGA box promoter occupancy and mechanism of cytokine-mediated down-regulation. Mol. Endocrinol. 12 (1998) 391-404
108. Sims J.E., Giri J.G., and Dower S.K. The two interleukin-1 receptors play different roles in IL-1 activities. Clin. Immunol. Immunopathol. 72 (1994) 9-14
109. Smith J.W., Urba II W.J., Curti B.D., Elwood L.J., Steis R.G., Janik R.E., Sharfman W.H., Miller L.L., Fenton R.G., Conlon K.C., Sznol M., Greekmore S.P., et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J. Clin. Oncol. 10 (1992) 1141-1152
110. Stevenson F.T., Torrano F., Locksley R.M., and Lovett D.H. Interleukin-1: The patterns of translation and intracellular distribution support alternative secretory mechanisms. J. Cell. Physiol. 152 (1992) 223-231
111. Symons J.A., Eastgate J.A., and Duff G.W. Purification and characterization of a novel soluble receptor for interleukin 1. J. Exp. Med. 174 (1991) 1251-1254
112. Tatakis D.N. Interleukin-1 and bone metabolism: A review. J. Peridontol. 64 (1993) 416-431
113. Tatar M., Bartke A., and Antebi A. The endocrine regulation of aging by insulin-like signals. Science 299 (2003) 1346-1351
114. Thissen J.P., and Verniers J. Inhibition by interleukin-1 beta and tumor necrosis factor-alpha of the insulin-like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology 138 (1997) 1078-1084
115. Thomas M.J., Kikuchi K., Bichell D.P., and Rotwein P. Characterization of deoxyribonucleic acid-protein interactions at a growth hormone-inducible nuclease hypersensitive site in the rat insulin-like growth factor-I gene. Endocrinology 136 (1995) 562-569
116. Thompson B.J.L., Shang C.A., and Waters M.J. Identification of genes induced by growth hormone in rat liver using cDNA arrays. Endocrinology 141 (2000) 4321-4324
117. Tollet-Egnell P., Flores-Morales A., Stavreus-Evers A., Sahlin L., and Norstedt G. Growth hormone regulation of SOCS-2, SOCS-3, and CIS messenger ribonucleic acid expression in the rat. Endocrinology 140 (1999) 3693-3704
118. Tollet-Egnell P., Parini P., Stahlberg N., Lonnstedt I., Lee N.H., Rudling M., Flores-Morales A., and Norstedt G. Growth hormone-mediated alteration of fuel metabolism in the aged rat as determined from transcript profiles. Physiol. Genomics 16 (2004) 261-267
119. Touw I.P., De Koning J.P., Ward A.C., and Hermans M.H. Signaling mechanisms of cytokine receptors and their perturbances in disease. Mol. Cell. Endocrinol. 160 (2000) 1-9
120. Van der Meer J.W.M., Barza M., Wolff S.M., and Dinarello C.A. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc. Natl. Acad. Sci. USA 85 (1988) 1620-1623
121. Vannier E., Miller L.C., and Dinarello C.A. Coordinated anti-inflammatory effects of interleukin-4: Interleukin-4 suppresses IL-1 production, but up-regulates gene expression of IL1 receptor antagonist. Proc. Natl. Acad. Sci. USA 89 (1992) 4076-4080
122. Vary T.C., and Kimball S.R. Sepsis-induced changes in protein synthesis: Differential effects on fast- and slow-twitch muscles. Am. J. Physiol. 262 (1992) C1513-C1519
123. Wang L., Wang X., and Adamo M.L. Two putative GATA motifs in the proximal exon 1 promoter of the rat insulin-like growth factor-I gene regulate basal promoter activity. Endocrinology 141 (2000) 1118-1126
124. Wang X., Talamantez J.L., and Adamo M.L. A CACCC box in the proximal exon 2 promoter of the rat insulin-like growth factor I gene is required for basal promoter activity. Endocrinology 139 (1998) 1054-1066
125. Webb A.C., Collins K.L., Auron P.E., Eddy R.L., Nakai H., Byers M.G., Haley W.M., and Shows T.B. Interleukin-1 gene assigned to long arm or chromosome 2. Lymphokine Res. 5 (1986) 77-85
126. Wilmore D.W. Catabolic illness: Strategies for enhancing recovery. N. Engl. J. Med. 325 (1991) 695-702
127. Wilmore D.W. Metabolic response to severe surgical illness: Overview. World J. Surg. 6 (2000) 705-711
128. Woelfle J., and Rotwein P. In vivo regulation of growth hormone-stimulated gene transcription by STAT5b. Am. J. Physiol. Endocrinol. Metab. 286 (2004) E393-E401
129. Woelfle J., Billiard J., and Rotwein P. Acute control of IGF-I gene transcription by growth hormone through Stat5b. J. Biol. Chem. 278 (2003) 22696-22702
130. Woelfle J., Chia D.J., and Rotwein P. Mechanisms of growth hormone action: Identification of conserved STAT5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J. Biol. Chem. 278 (2003) 51261-51266
131. Woelfle J., Chia D.J., Massart-Schlesinger M.B., Moyano P., and Rotwein P. Molecular physiology, pathology, and regulation of the growth hormone/insulin-like growth factor-I system. Pediatr. Nephrol. 20 (2005) 295-302
132. Wolf M., Bohm S., Brand M., and Kreymann G. Proinflammatory cytokines interleukin 1 beta and tumor necrosis factor alpha inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. Eur. J. Endocrinol. 135 (1996) 729-737
133. Yoshizato H., Fujikawa T., Soya H., Tanaka M., and Nakashima K. The growth hormone (GH) gene is expressed in the lateral hypothalamus: Enhancement by GH-releasing hormone and repression by restraint stress. Endocrinology 139 (1998) 2545-2551
134. Yumet G., Shumate M.L., Bryant D.P., Lin C.M., Lang C.H., and Cooney R.N. Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis. Am. J. Physiol. Endocrinol. Metab. 283 (2002) E472-E481
135. Yumet G., Shumate M.L., Bryant D.P., Lang C.H., and Cooney R.N. Hepatic growth hormone resistance during sepsis is associated with increased suppressors of cytokine signaling expression and impaired growth hormone signaling. Crit. Care Med. 34 (2006) 1420-1427
136. Zamir O., Hasselgren P.O., O'Brien W.O., Thompson R.C., and Fischer E.J. Muscle protein breakdown during endotoxemia in rats and after treatment with IL-1ra. Ann. Surg. 216 (1992) 381-387
137. Zhu T., Goh E.L.K., Graichen R., Ling L., and Lobie P.E. Signal transduction via the growth hormone receptor. Cell Signal 13 (2001) 599-616